- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Zenas BioPharma Prices $300M Capital Raise in Dual Offering | 3 | Seeking Alpha | ||
| Fr | Zenas BioPharma prices $200M convertible notes, $100M stock sale | 3 | Investing.com | ||
| Fr | Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million | 1 | GlobeNewswire (USA) | ||
| Do | Zenas BioPharma launches convertible notes, stock offerings | 1 | Investing.com | ||
| Do | Zenas BioPharma announces concurrent public offerings of convertible senior notes and common stock | 1 | Seeking Alpha | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock | 3 | GlobeNewswire (USA) | ||
| 16.03. | Guggenheim raises Zenas Biopharma stock price target to $55 on pipeline progress | 2 | Investing.com | ||
| 16.03. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 16.03. | Guggenheim hebt Kursziel für Zenas Biopharma nach Pipeline-Fortschritten auf 55 US-Dollar an | 1 | Investing.com Deutsch | ||
| 16.03. | Morgan Stanley hebt Kursziel für Zenas Biopharma wegen IgG4-RD-Aussichten an | 2 | Investing.com Deutsch | ||
| 16.03. | Morgan Stanley raises Zenas Biopharma stock price target on IgG4-RD outlook | 1 | Investing.com | ||
| 16.03. | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 16.03. | Zenas BioPharma, Inc. GAAP EPS of -$4.54 misses by $3.66 | 1 | Seeking Alpha | ||
| 16.03. | Zenas BioPharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 16.03. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.02. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 09.02. | Zenas BioPharma's MS drug shows 95% reduction in brain lesions | 3 | Investing.com | ||
| 09.02. | Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 | 1 | GlobeNewswire (USA) | ||
| 04.02. | Zenas Bio rises after over $1M stock purchase by CEO | 1 | Seeking Alpha | ||
| 04.02. | Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | 2 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
81 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 303,90 | -1,04 % | Amgen: Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis | Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention
VESALIUS-CV Subgroup Findings Reinforce Benefit... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 653,40 | -0,55 % | Sanofi: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid | Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Approval in moderate-to-severe patients was based on pivotal study results... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,870 | -0,71 % | BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations | ||
| ARROWHEAD PHARMACEUTICALS | 49,830 | -5,59 % | Arrowhead Pharma stock rating reiterated at Buy by TD Cowen | ||
| INSMED | 134,00 | +3,88 % | Weekly Buzz: Corcept Therapeutics Wins FDA Nod In Cancer; Merck & Co. Acquires Terns Pharmaceuticals; Insmed Meets Trial Goals But Valneva Misses | KENILWORTH (NJ) (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Japan, EU withdrawals, mergers, and clinical trial data readouts spanning lung disease... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 34,940 | -0,74 % | Swedish Orphan Biovitrum AB: EMA validates indication extension application for Tryngolza (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) | STOCKHOLM, March 30, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indication extension application for Tryngolza (olezarsen)... ► Artikel lesen | |
| SCHOLAR ROCK | 36,200 | -4,74 % | AKTIONÄR-Tipp Scholar Rock mit Kurssprung - das ist der Grund | Die Aktie des Biotech-Unternehmens Scholar Rock konnte am Freitag einen satten Kurssprung von mehr als 20 Prozent hinlegen. Die Gesellschaft hat ihre Quartalszahlen vorgelegt und in diesem Rahmen positive... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 29,800 | +3,47 % | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly | SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health... ► Artikel lesen | |
| PROQR THERAPEUTICS | 1,336 | +0,30 % | Growing Optimism About ProQR Therapeutics (PRQR)'s RNA Editing Platform and Future Clinical Catalysts | ||
| THERATECHNOLOGIES | 2,780 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 06.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.10.2025.ISIN NameAT0000A3PGY9 UBM... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 0,520 | -4,94 % | Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results | ~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 45,680 | -0,26 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| TEVOGEN BIO | 4,310 | 0,00 % | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 276,44 | -4,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| QIAGEN | 34,540 | -1,50 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,030 (-0,16 %) liegt der Kurs bei 18,245 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.